# 3T Biosciences

> 3T Biosciences is a South San Francisco immunotherapy developer that uses patient T-cell responses, experimental target libraries and machine learning to discover cancer targets and screen TCR-based medicines for off-target activity. It is developing its own pipeline and collaborates with pharmaceutical and academic partners.

- **Founded:** 2017
- **Headquarters:** South San Francisco, United States
- **Founders:** Leah Sibener (Co-founder; scientific advisor), Marvin Gee (Co-founder; chief research officer), K. Christopher Garcia (Scientific co-founder; scientific advisory board chair)
- **Products:** 3T-TRACE, 3T-403, TCRm bispecific, peptide vaccine and TCR cell-therapy approaches
- **Notable:** Launched publicly in 2022 with a $40 million Series A., Signed a second Boehringer Ingelheim research agreement in 2024 after the initial 2023 collaboration., Reported a preclinical lead candidate, 3T-403, in a 2025 AACR abstract.

## Products & services

- **3T-TRACE** — T Cell Receptor Antigen and Cross-Reactivity Engine; combines patient immune profiling, high-diversity target libraries, high-throughput screening and machine learning for target identification and specificity analysis.
- **3T-403** — Preclinical CD3 bispecific T-cell engager using a TCR-mimetic antibody against a novel peptide-HLA target; described in a 2025 AACR abstract for several solid-tumor indications.
- **TCRm bispecific, peptide vaccine and TCR cell-therapy approaches** — Therapeutic modalities the company says its target discovery technology can support; availability and individual development stages vary.

## Achievements

- Launched publicly in 2022 with a $40 million Series A.
- Signed a second Boehringer Ingelheim research agreement in 2024 after the initial 2023 collaboration.
- Reported a preclinical lead candidate, 3T-403, in a 2025 AACR abstract.
- Expanded research collaborations across the United States and Europe in 2024.

## Latest updates

- **2026-03** — Appointed Rebeca Villarreal-Barragan head of clinical operations as the company prepared its TCR-based pipeline for clinical studies.
- **2026-01** — Named Behzad Kharabi chief medical officer and Karen Knudsen to the board.
- **2025-04** — AACR abstract described preclinical lead 3T-403, a TCR-mimetic CD3 bispecific T-cell engager.
- **2025-03** — Promoted co-founder Marvin Gee to chief research officer and appointed Barbara Sennino head of early development.

## Links

- Website: https://3tbiosciences.com/
- LinkedIn: https://www.linkedin.com/company/3tbiosciences
- Twitter/X: https://twitter.com/3tbio

---

Profile page: https://yespress.io/3t-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-09-28